MedPath

Integrated blood glucose monitoring with insulin pumps versus standard method - a randomised crossover trial

Not Applicable
Conditions
Type 1 diabetes mellitus
Metabolic and Endocrine - Diabetes
Registration Number
ACTRN12611000142932
Lead Sponsor
Murdoch Children's Research Institute
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Users due a pump upgrade within next 13 to 24 months

Exclusion Criteria

1) Have previously experienced significant skin reactions to pump giving sets, or other reactions which may mean that changing to a different pump may result in similar reaction and/or study withdrawal
2) Non-English speaking users

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Mean Number of finger-prick blood glucose measurements entered into and recorded in participants' pump[6 months and 12 months (after each phase of trial)]
Secondary Outcome Measures
NameTimeMethod
Metabolic control as measured by HbA1c[3, 6, 9 and 12 months];User device satisfaction as measured by the Insulin Delivery System Rating Questionnaire (IDSRQ)[6 and 12 months];Information available to download from pump:<br>-total daily insulin dose<br>-number of boluses and percentage of dose given as a correction factor<br>-number of carbohydrate entries<br>-blood glucose variability<br>-% of insulin delivered as basal versus bolus<br>-% of blood glucose measurements within target range[3, 6, 9 and 12 months<br>Also assessed at 6 weeks after starting a new phase for assessment of novelty or carryover effect];Frequency of participants' contacts with the support team[6 and 12 months]
© Copyright 2025. All Rights Reserved by MedPath